>
Biomx Inc logo

PHGE.U - Biomx Inc Share Price

$10.74 0.0  0.0%

Sector
Healthcare
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6850
Bullish
Bearish
Unlock PHGE.U Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 01st Jan 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BiomxInc revenues was not reported. Net loss increased 46% to$30.1M. Higher net loss reflects Research and development(R&D) expenses, increase from $4.8M to $9.9M (expense),Stock-based Compensation in R&D increase from $450K to$1.8M (expense), Salaries and related expenses increase of17% to $9.2M (expense). Basic Earnings per Share excludingExtraordinary Items increased from -$3.66 to -$1.30.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PHGE.U Revenue Unlock PHGE.U Revenue

Net Income

PHGE.U Net Income Unlock PHGE.U Revenue

Normalised EPS

PHGE.U Normalised EPS Unlock PHGE.U Revenue

PE Ratio Range

PHGE.U PE Ratio Range Unlock PHGE.U Revenue

Dividend Yield Range

PHGE.U Dividend Yield Range Unlock PHGE.U Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PHGE.U EPS Forecasts Unlock PHGE.U Revenue
Profile Summary

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Directors
Last Annual January 1st, 1970
Last Interim January 1st, 1970
Incorporated November 1, 2017
Public Since December 14, 2018
No. of Shareholders: 75
No. of Employees: 95
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NYSE MKT
Shares in Issue
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
PHGE.U Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PHGE.U
Upcoming Events for PHGE.U
Similar to PHGE.U
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.